The SAFE Drugs Act of 2026 amends the Federal Food, Drug, and Cosmetic Act to constrain how often pharmacies and providers can compound products that essentially replicate commercially available drugs, to require annual reporting when compounding is provided across state lines, and to tighten oversight of outsourcing facilities through registration, pre-use inspections and routine reinspections. It also removes a fixed statutory base fee for certain establishments and replaces it with a discretionary amount determined by the Secretary to fund safety activities for compounded products.
This package centralizes more information with FDA and raises inspection and registration obligations for some compounders. The bill is focused on preventing large-scale production of copycat drugs outside the normal drug approval and manufacturing framework, while creating new compliance tasks for compounding pharmacies, outsourcing facilities, and prescribing practitioners.
At a Glance
What It Does
The bill limits compounding of products that are essentially copies of commercially available drugs to 20 instances in a single month, requires annual reporting to the Secretary when compounders serve out‑of‑state patients more than that threshold, and directs FDA to inspect outsourcing facilities that compound above a 100‑per‑year threshold (initial inspection before first compounding and biennial reinspections). It also removes a fixed $15,000 base establishment fee and lets the Secretary set a base amount to fund compound-product safety activities.
Who It Affects
State-licensed compounding pharmacies, physician compounders who ship to out‑of‑state patients, registered outsourcing facilities (including those that compound repeatedly), and the FDA (which gains new reporting and inspection duties). Commercial manufacturers of approved drugs and hospital pharmacies (which the bill excludes from the new reporting rule) are also implicated.
Why It Matters
The measure narrows the functional space for mass production of unapproved or effectively duplicated products via compounding, increases FDA visibility into cross‑state compounding flows, and formalizes inspection cadence for higher‑volume outsourcers—shifting operational and compliance burdens and giving FDA funding flexibility to support enforcement.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill alters Section 503A of the FD&C Act to draw a bright line around how often a compounder may make a product that is essentially a copy of a commercially available drug: no compounder may, in a single month, compound such a product more than 20 times. The statute defines an “essentially a copy” product by two elements: it contains an active ingredient present in a marketed product, and the compound must not include a patient‑specific change that, in the prescribing practitioner’s professional judgment, creates a significant difference for that patient.
That language preserves clinician discretion while making the volume cap explicit.
Beyond the cap, the bill adds a new annual reporting duty for any pharmacy, facility, or physician that compounds more than 20 instances in a month when the recipients reside outside the State where compounding occurs. Reports must list each type of compounded product meeting that description and the monthly totals; they are due by year‑end and must follow FDA’s form and manner.
The reporting rule explicitly excludes on‑premises hospital pharmacies compounding for hospital patients.For outsourcing facilities governed by Section 503B, the bill creates a tiered inspection regime: an outsourcing facility that compounds any drug more than 100 times in a calendar year is treated as “large‑scale,” triggering a pre‑use inspection before it compounds that product and a required reinspection at least every two years. The bill also removes an exemption in Section 510(g)(1) so that outsourcing facilities—previously treated differently in some registration contexts—are captured for registration and associated obligations.
Those two changes take effect six months after enactment.Finally, the measure strips a fixed statutory $15,000 base establishment fee and replaces it with authority for the Secretary to set a base amount “deemed appropriate” to fund safety activities related to compounded products. That gives FDA discretion to tune user fees to the programmatic needs it identifies, rather than being limited to the current statutory number.
The Five Things You Need to Know
The bill amends 503A to prohibit compounding a drug that is “essentially a copy” of a marketed product more than 20 times in any single month.
It defines “essentially a copy” as any product containing an active ingredient found in a marketed product where no patient‑specific change produces a significant difference as judged by the prescribing practitioner.
Beginning with calendar year 2025, compounders who exceed 20 such instances in a month for patients who reside outside the State where compounding occurs must submit an annual report to the Secretary listing product types and monthly totals.
The bill designates an outsourcing facility as “large‑scale” if it compounds any drug product more than 100 times in a calendar year and requires an inspection before first compounding that product and at least biennial reinspections thereafter; the registration change removes certain exemptions so outsourcing facilities are subject to registration obligations.
Section 744K’s $15,000 statutory base establishment fee is replaced with a base amount set by the Secretary to fund compounded‑product safety activities, giving FDA fee‑setting discretion.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Numeric cap and definition of 'essentially a copy' for compounded products
This provision inserts a quantitative limit—no more than 20 instances per month—on compounding products that are essentially copies of commercially available drugs. It provides a two‑part definition: (1) presence of an active ingredient found in a marketed product, and (2) absence of a patient‑specific change that the prescribing practitioner determines yields a significant difference. Practically, compliance will require compounders and prescribers to document why a compounded product is not merely duplicative, elevating clinical judgment into a statutory compliance touchpoint.
Annual reporting when cross‑state compounding exceeds monthly threshold
New subsection 503A(d) obligates any pharmacy, facility, or physician that compounds more than 20 qualifying instances in a month for patients who live outside the State where compounding occurs to submit an annual report to the Secretary. The report must identify each product type and the monthly counts and is due by year‑end. The bill excludes hospital pharmacies compounding for their hospital patients, limiting reporting to non‑hospital operations and emphasizing cross‑state distribution as the concern.
Inspection regime for large‑scale outsourcing facilities
The bill adds a new inspection trigger for outsourcing facilities that compound any drug product more than 100 times in a calendar year. Those facilities must undergo an inspection before compounding that product for the first time and must be reinspected at least every two years. The practical effect is to create a predictable inspection cadence for higher‑volume outsourcers and to reduce the chance that a facility can begin sizable production without FDA on‑site review.
Registration capture for outsourcing facilities and six‑month delay
The bill narrows the exemption in Section 510(g)(1) so that outsourcing facilities (as defined in 503B(d)(4)) are not exempt from registration obligations. Those registration and related reporting duties, together with the inspection changes, become applicable six months after enactment—giving a brief runway for affected facilities to come into compliance but also creating a near‑term implementation demand on FDA and industry.
Secretary discretion to set base establishment fee
The statute’s prior fixed base amount for establishment fees ($15,000) is repealed and replaced with language authorizing the Secretary to determine a base amount sufficient to fund safety activities for compounded products. That change gives FDA flexibility to calibrate fees to program needs but transfers pricing discretion away from the statute to the agency.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients concerned about safety of compounded medications — The bill aims to curb mass production of copycat products and increase FDA visibility into compounding that crosses state lines, which could reduce contamination and quality risks associated with large‑scale compounding outside regulated manufacturing.
- FDA and federal regulators — The agency receives new reporting streams, clearer inspection triggers, and fee‑setting authority to fund oversight activities, improving its ability to target enforcement and safety work.
- Manufacturers of commercially approved drugs — By limiting how often compounders can replicate marketed products, the bill reduces a pathway for off‑label commercial substitution that can undercut approved manufacturers’ markets.
Who Bears the Cost
- Independent compounding pharmacies and physician compounders — They face new compliance tasks: tracking monthly counts, compiling and submitting annual reports for out‑of‑state recipients, documenting practitioner determinations that justify deviations from marketed products, and potential changes in business models if previously high‑volume copying is curtailed.
- Outsourcing facilities that exceed the 100/year threshold — These entities must prepare for pre‑use inspections, biennial reinspections, register where they may not have before, and potentially pay higher user fees set by FDA, increasing operating costs and administrative burden.
- FDA (implementation burden) and possibly States — Although FDA gains fee authority, it must build processes for receiving reports, performing inspections on an accelerated schedule, and adjudicating compliance, which can strain resources during the six‑month ramp‑up period and beyond.
- Patients who relied on compounded copies for cost or availability reasons — If compounders reduce production of copycat products, some patients may lose informal access to lower‑cost or locally produced alternatives, at least until commercial supply or authorized alternatives respond.
Key Issues
The Core Tension
The central trade‑off is between preventing mass‑produced, effectively unregulated copies of marketed drugs (protecting safety and the integrity of the drug approval system) and preserving access to customized compounded therapies without imposing burdens that shrink local compounding capacity, raise costs, or push activity outside the regulated reporting and inspection perimeter.
The bill creates several implementation gray areas. First, the counting rules are not fully specified: it is unclear whether the 20‑times monthly cap and the 100/year threshold are counted per NDC/active ingredient, per specific formulation, per lot, or per prescriber‑patient pair.
That ambiguity will affect which entities fall into the reporting and inspection buckets and how easily they can comply. Second, the bill relies on the prescribing practitioner’s determination that a patient‑specific change produces a “significant difference,” but the statute does not define “significant” or set documentation standards—leaving room for inconsistent application and potential legal exposure for prescribers and pharmacists.
The reporting requirement focuses solely on compounding provided to patients who reside outside the State where compounding occurs, which creates incentives to keep distribution local or to route shipments through in‑state addresses to avoid reporting. The hospital pharmacy exclusion is sensible for inpatient care but could be used strategically to route outpatient compounding through hospital affiliates.
Finally, giving the Secretary discretion to set the base establishment fee increases flexibility but also creates uncertainty for small facilities trying to budget for new user fees; it shifts an economic policy choice from statute to agency rulemaking and could be challenged if fees are set aggressively without clear cost justification.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.